Alteplase Treatment in Acute Stroke: Incorporating Food and Drug Administration Prescribing Information into Existing Acute Stroke Management Guide

Research output: Contribution to journalReview article

5 Scopus citations

Abstract

Despite strong evidence that intravenous tissue plasminogen activator (tPA) improves outcomes in acute ischemic stroke patients, its use in clinical practice remains modest. Complex eligibility criteria have been postulated as barriers to greater utilization. Further complicating this has been multiple guidelines and prescribing labels that have been published since first being approved for use in 1996. In this review, several warning and exclusion criteria for tPA in acute ischemic stroke are reviewed with the goal of providing readers a nuanced understanding of historical context and available evidence to make informed decision.

Original languageEnglish (US)
Article number53
JournalCurrent Atherosclerosis Reports
Volume18
Issue number8
DOIs
StatePublished - Aug 1 2016

Keywords

  • Alteplase
  • Food and Drug Administration
  • Guidelines
  • Ischemic stroke
  • Tissue plasminogen activator

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Alteplase Treatment in Acute Stroke: Incorporating Food and Drug Administration Prescribing Information into Existing Acute Stroke Management Guide'. Together they form a unique fingerprint.

  • Cite this